VitalConnect granted Emergency Use Authorisation for cardiac monitoring in COVID-19 patients

VitalPatch biosensor is now authorised to detect changes in the QT interval of hospitalised patients undergoing drug treatment for COVID-19

VitalConnect has been granted Emergency Use Authorisation (EUA) status by the US Food and Drug Administration (FDA) as part of the response to the COVID-19 pandemic. The EUA will enhance the capabilities of the VitalPatch and continuous patient monitoring technology, the Vista Solution.

Under the FDA EUA, the VitalPatch is now authorised to detect changes in the QT interval of hospitalised patients undergoing drug treatment for COVID-19. Drugs such as Hydroxychloroquine and Chloroquine, being used to treat COVID-19, can cause prolongation of QT intervals for patients and may lead to life-threatening arrhythmias. VitalConnect QT interval detection capabilities help enable clinicians to remotely and continuously monitor patients in real-time who may have, or develop, an elongation of QT interval as a result of their COVID-19 treatment.

“COVID-19 presents a myriad of symptoms and clinicians need access to medical devices that allow them to monitor and manage those symptoms in real-time in order to create the most appropriate treatment plans for each individual,” said Joe Roberson, chief medical officer of VitalConnect. “The enhancement of the VitalPatch receiving Emergency Use Authorisation for QT-interval detection will enable this platform to further support clinicians who are on the frontlines of treating this virus.”

As clinicians recognise and analyse the impact of COVID-19 on the heart, the ability to monitor other key vital signs provides critical information needed to develop effective treatment plans. Vista Solution, with the VitalPatch and optional 3rd party devices, measures 11 physiological vitals continuously and in real-time including body temperature, heart rate, heart rate variability, respiratory rate, and blood oxygen saturation levels.

“As we learn more about the novel coronavirus, the VitalPatch and Vista Solution platform can make a big impact on the treatment of the many people suffering across our nation,” said Peter Van Haur, CEO, VitalConnect. “Continuous, real-time monitoring enables next-level care and efficiency in the hospital and in post-discharge settings that will help clinicians treating patients on the frontlines today.”


Please enter your comment!
Please enter your name here